Merck and Ridgeback Report Results of Lagevrio (molnupiravir) in P-III (MOVe-OUT) Trial for the Treatment of COVID-19
Shots:
- The P-III (MOVe-OUT) trial evaluates molnupiravir (800mg, bid) vs PBO in non-hospitalized, unvaccinated adult patients with COVID-19 who had 1 risk factor associated with poor disease outcomes
- In a pre-specified exploratory EPs i.e., a lower proportion of patients in the MITT population had an acute care visit & COVID-19-related acute care visit (7.2% vs 10.6%) @29 days & (6.6% vs 10.0%) with RRR (32.1% & 33.8%), fewer patients required respiratory interventions with a RRR of 34.3%. The results were published in the Annals of Internal Medicine
- In post hoc analyses, participants in the safety population showed reductions in mean CRP values, improvements in mean change from baseline SpO2 values & patients required respiratory interventions with a RRR of 21.3%
Ref: Businesswire| Image: Merck
Ref: Globenewswire| Image: Novartis
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
